Phillip Dolamore
Plus aucun poste en cours
Profil
Phillip Dolamore is Head of Portfolio and Project Management for GlycoForm Ltd.
He joined GlycoForm as a Consultant in 2008.
Prior to joining GlycoForm, he was Manager of Strategy and Performance, Project Manager, Research Leader, Cardiovascular Pharmacologist and Histopathology Technician for Glaxo and GlaxoWellcome.
He has 20 years of experience in developing pharmaceuticals.
Mr. Dolamore received a degree in Pharmacology from Leeds University in 1973.
Anciens postes connus de Phillip Dolamore
| Sociétés | Poste | Fin |
|---|---|---|
| Glaxo, Inc. | Corporate Officer/Principal | - |
| GlaxoWellcome /Pharmocology Unit/ | Corporate Officer/Principal | - |
GlycoForm Ltd.
 GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | Health Technology |
| Glaxo, Inc. | |
| GlaxoWellcome /Pharmocology Unit/ | Commercial Services |
